Search

Your search keyword '"Angela Puente"' showing total 26 results
Start Over Author "Angela Puente" Journal journal of hepatology
26 results on '"Angela Puente"'

1. Rivaroxaban improves survival and decompensation in cirrhotic patients with moderate liver dysfunction. Double-blind, placebo-controlled trial

Author

Sanchez, Angela Puente, primary, Turon, Fanny, additional, Martinez, Javier, additional, Fortea, Jose Ignacio, additional, Hernandez-Guerra, Manuel, additional, Alvarado-Tapias, Edilmar, additional, Pons, Monica, additional, Magaz, Marta, additional, Llop, Elba, additional, Álvarez-Navascués, Carmen, additional, Alonso, José Castellote, additional, Berenguer, Marina, additional, Masnou, Helena, additional, Bañares, Rafael, additional, Casado, Marta, additional, Ampuero, Javier, additional, Casanovas, Georgina, additional, Redondo, Carlos, additional, Huelin, Patricia, additional, Téllez, Luis, additional, Arraez, Dalia Morales, additional, Rodríguez, Manuel, additional, Aguilera, Victoria, additional, Baiges, Anna, additional, Hernandez-Gea, Virginia, additional, Perelló, Christie, additional, Calleja Panero, José Luis, additional, Genesca, Joan, additional, Villanueva, Càndid, additional, González-Alayón, Carlos, additional, Albillos, Agustin, additional, Crespo, Javier, additional, and Garcia Pagan, Juan Carlos, additional

Published
2023
Full Text
View/download PDF

2. Validation of automatic cell counting based on impendaciometry and flow cytometry in ascitic fluid

Author

Herrán, Aitor Odriozola, primary, Antón, Ángela, additional, Sanchez, Angela Puente, additional, Sardina, Romina García, additional, Segundo Arribas, David San, additional, Del Barrio Azaceta, María, additional, Alonso, Sara, additional, Echavarria, Victor, additional, González, Andrea, additional, Ribes, Carmen, additional, Gutierrez, Carlos, additional, López-Hoyos, Marcos, additional, Cuadrado, Antonio, additional, Adam, Valeria, additional, Crespo, Javier, additional, and Fortea, Jose Ignacio, additional

Published
2023
Full Text
View/download PDF

3. Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension

Author

Jose Luis Calleja, Javier Martínez, Xavier Forns, Adolfo Gallego, Edilmar Alvarado-Tapias, Rafael Bañares, Anna Baiges, Elba Llop, Virginia Hernández-Gea, José Ignacio Fortea, Angela Puente, Agustín Albillos, Sergio Rodríguez-Tajes, Càndid Villanueva, Sabela Lens, Luís Ibáñez-Samaniego, Zoe Mariño, Juan Carlos García-Pagán, Jaume Bosch, and Xavier Torras

Subjects
Liver Cirrhosis, Male, 0301 basic medicine, medicine.medical_specialty, Cirrhosis, Sustained Virologic Response, Portal venous pressure, Population, Hemodynamics, Hepacivirus, Antiviral Agents, Risk Assessment, Gastroenterology, Time, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Hypertension, Portal, Ascites, medicine, Humans, Decompensation, education, education.field_of_study, Hepatology, business.industry, Hepatitis C, Hepatitis C, Chronic, Middle Aged, medicine.disease, 030104 developmental biology, Liver, Spain, Disease Progression, Elasticity Imaging Techniques, Portal hypertension, Female, 030211 gastroenterology & hepatology, medicine.symptom, business, Follow-Up Studies
Abstract

Clinically significant portal hypertension (CSPH), defined as a hepatic venous pressure gradient (HVPG) ≥10 mmHg, persists 24 weeks after sustained virological response (SVR) in up to 78% of patients with HCV-related cirrhosis treated with direct-acting antivirals. These patients remain at risk of decompensation. However, long-term paired clinical and hemodynamic data are not available for this population.We conducted a prospective multicenter study in 226 patients with HCV-related cirrhosis and CSPH who achieved SVR after antiviral therapy. Patients with CSPH 24 weeks after end of treatment (SVR24) were offered another hemodynamic assessment 96 weeks after end of treatment (SVR96).All patients were clinically evaluated. Out of 176 patients with CSPH at SVR24, 117 (66%) underwent an HVPG measurement at SVR96. At SVR96, 55/117 (47%) patients had HVPG10 mmHg and 53% had CSPH (65% if we assume persistence of CSPH in all 59 non-evaluated patients). The proportion of high-risk patients (HVPG ≥16 mmHg) diminished from 41% to 15%. Liver stiffness decreased markedly after SVR (median decrease 10.5 ± 13 kPa) but did not correlate with HVPG changes (30% of patients with liver stiffness measurement13.6 kPa still had CSPH). Seventeen (7%) patients presented with de novo/additional clinical decompensation, which was independently associated with baseline HVPG ≥16 mmHg and history of ascites.Patients achieving SVR experienced a progressive reduction in portal pressure during follow-up. However, CSPH may persist in up to 53-65% of patients at SVR96, indicating persistent risk of decompensation. History of ascites and high-risk HVPG values identified patients at higher risk of de novo or further clinical decompensation.As a major complication of cirrhosis, clinically significant portal hypertension (CSPH) is associated with adverse clinical outcomes. Herein, we show that CSPH persists at 96 weeks in just over half of patients with HCV-related cirrhosis, despite HCV elimination by direct-acting antivirals. Despite viral cure, patients with CSPH at the start of antiviral treatment remain at long-term risk of hepatic complications and should be managed accordingly.

Published
2020
Full Text
View/download PDF

4. Non-invasive tests for clinically significant portal hypertension after HCV-cure-individual patient data meta-analysis and validation

Author

Georg Semmler, Sabela Lens, Elias Laurin Meyer, Anna Baiges, Edilmar Alvarado-Tapias, Elba Llop, Javier Martinez, Philipp Schwabl, Ezequiel Mauro, Laia Escude, Cristina Diez, Luis Ibañez, Jose Ignacio Fortea, Angela Puente, Marta Abadia, Ji-Dong Jia, Hitoshi Yoshiji, Sven Francque, Emmanuel Tsochatzis, Jaime Bosch, Rafael Bañares, Gonzalo Crespo, Thomas Reiberger, Càndid Villanueva, Xavier Forns, Juan Carlos Garcia Pagan, and Mattias Mandorfer

Subjects
Hepatology
Published
2022
Full Text
View/download PDF

7. GS-003 - Rivaroxaban improves survival and decompensation in cirrhotic patients with moderate liver dysfunction. Double-blind, placebo-controlled trial

Author

Sanchez, Angela Puente, Turon, Fanny, Martinez, Javier, Fortea, Jose Ignacio, Hernandez-Guerra, Manuel, Alvarado-Tapias, Edilmar, Pons, Monica, Magaz, Marta, Llop, Elba, Álvarez-Navascués, Carmen, Alonso, José Castellote, Berenguer, Marina, Masnou, Helena, Bañares, Rafael, Casado, Marta, Ampuero, Javier, Casanovas, Georgina, Redondo, Carlos, Huelin, Patricia, Téllez, Luis, Arraez, Dalia Morales, Rodríguez, Manuel, Aguilera, Victoria, Baiges, Anna, Hernandez-Gea, Virginia, Perelló, Christie, Calleja Panero, José Luis, Genesca, Joan, Villanueva, Càndid, González-Alayón, Carlos, Albillos, Agustin, Crespo, Javier, and Garcia Pagan, Juan Carlos

Published
2023
Full Text
View/download PDF

8. Persistently low platelet count and splenomegaly after treatment with oxaliplatin as markers of development of portal sinusoidal vascular disease

Author

Sanchez, Angela Puente, primary, del Pozo, Carmen, additional, Serrano, Marina, additional, Giraldez-Gallego, Alvaro, additional, Luis, Tellez, additional, Martinez, Javier, additional, Magaz, Marta, additional, Ibañez, Luis, additional, Garcia, Julia, additional, Llop, Elba, additional, Álvarez-Navascués, Carmen, additional, Romero-Gutiérrez, Marta, additional, Fortea, Jose Ignacio, additional, Lopez, Carlos Lopez, additional, Albillos, Agustin, additional, Hernandez-Gea, Virginia, additional, Garcia Pagan, Juan Carlos, additional, Bañares, Rafael, additional, and Crespo, Javier, additional

Published
2020
Full Text
View/download PDF

10. Persistently low platelet count and splenomegaly after treatment with oxaliplatin as markers of development of portal sinusoidal vascular disease

Author

Angela Puente Sanchez, Carmen del Pozo, Marina Serrano, Alvaro Giraldez-Gallego, Tellez Luis, Javier Martinez, Marta Magaz, Luis Ibañez, Julia Garcia, Elba Llop, Carmen Álvarez-Navascués, Marta Romero-Gutiérrez, Jose Ignacio Fortea, Carlos Lopez Lopez, Agustin Albillos, Virginia Hernandez-Gea, Juan Carlos Garcia Pagan, Rafael Bañares, and Javier Crespo

Subjects
Hepatology
Published
2020
Full Text
View/download PDF

11. FRI-373-Mismatch in C-locus Eplets between donor and recipient as independent factor of acute T-cell mediated rejection in liver transplantation

Author

Angela Puente Sanchez, Marcos López-Hoyos, Javier Crespo, José Ignacio Fortea, Fernando Casafont, David San Segundo, Sandra Guiral, Emilio Fábrega, and Antonio Cuadrado

Subjects
medicine.anatomical_structure, Hepatology, T cell, medicine.medical_treatment, medicine, Cancer research, Locus (genetics), Liver transplantation, Biology, Independent factor
Published
2019
Full Text
View/download PDF

12. THU-293-Increased risk of advanced liver disease independently of classic metabolic risk factors or drug induced hepatotoxicity in patients with psoriasis

Author

Loste, María Teresa Arias, primary, Iruzubieta, Paula, additional, Rasines, Laura, additional, Duque, Juan Carlos Rodriguez, additional, Fortea, Jose Ignacio, additional, Garcia, Agustin, additional, Sanchez, Angela Puente, additional, Armesto, Susana, additional, and Crespo, Javier, additional

Published
2019
Full Text
View/download PDF

14. THU-293-Increased risk of advanced liver disease independently of classic metabolic risk factors or drug induced hepatotoxicity in patients with psoriasis

Author

Susana Armesto, Paula Iruzubieta, Laura Rasines, Agustin Garcia, Angela Puente Sanchez, Javier Crespo, M.T.A. Loste, José Ignacio Fortea, and Juan Carlos Rodriguez Duque

Subjects
medicine.medical_specialty, Hepatology, business.industry, Metabolic risk, medicine.disease, Gastroenterology, Liver disease, Increased risk, Internal medicine, Psoriasis, Medicine, In patient, business, Drug induced hepatotoxicity
Published
2019
Full Text
View/download PDF

15. PS-017-Long-term impact of sustained virological response on systemic and pulmonary hemodynamics in HCV-cirrhotic patients with portal hypertension

Author

Isabel Blanco, Fanny Turon, Xavier Torras, Tanya Orizaga, garcia pagan juan carlos, Luis Ibañez, Zoe Mariño, Rafael Bañares, Anna Baiges, Xavier Forns, Edilmar Alvarado, Virginia Hernández-Gea, Càndid Villanueva, Joan Albert Barberà, Angela Puente, Jaume Bosch, Sabela Lens, and José Ignacio Fortea

Subjects
Virological response, medicine.medical_specialty, Hepatology, business.industry, Internal medicine, Cardiology, medicine, Portal hypertension, business, medicine.disease, Pulmonary hemodynamics, Term (time)
Published
2019
Full Text
View/download PDF

16. SAT-256-Influence of metabolic syndrome on fibrosis regression regulated by LOXL-2 after SVR

Author

Angela Puente, Miguel Posadas, José Ignacio Fortea, Javier Crespo, Agustin Garcia, Joaquín Cabezas, Laura Rasines, Susana Llerena, M.T.A. Loste, Paula Iruzubieta, and Emilio Fábrega

Subjects
Oncology, medicine.medical_specialty, Hepatology, Fibrosis, business.industry, Internal medicine, medicine, Metabolic syndrome, medicine.disease, business, Regression
Published
2019
Full Text
View/download PDF

17. FRI278 - Persistently low platelet count and splenomegaly after treatment with oxaliplatin as markers of development of portal sinusoidal vascular disease

Author

Sanchez, Angela Puente, del Pozo, Carmen, Serrano, Marina, Giraldez-Gallego, Alvaro, Luis, Tellez, Martinez, Javier, Magaz, Marta, Ibañez, Luis, Garcia, Julia, Llop, Elba, Álvarez-Navascués, Carmen, Romero-Gutiérrez, Marta, Fortea, Jose Ignacio, Lopez, Carlos Lopez, Albillos, Agustin, Hernandez-Gea, Virginia, Garcia Pagan, Juan Carlos, Bañares, Rafael, and Crespo, Javier

Published
2020
Full Text
View/download PDF

18. Long-term impact of HCV eradication after all-oral therapy in patients with clinical significant portal hypertension

Author

Anna Baiges, Luis Ibañez, Xavier Forns, Jaime Bosch, R. Bañares, José Ignacio Fortea, Sabela Lens, J.C. Garcia-Pagan, Edilmar Alvarado, C. Villanueva, Xavier Torras, José Luis Martínez, Elba Llop, José Luis Calleja Panero, Zoe Mariño, Angela Puente, María-Carlota Londoño, Virginia Hernández-Gea, and A. Albillos

Subjects
0301 basic medicine, medicine.medical_specialty, Hepatology, business.industry, medicine.disease, Term (time), 03 medical and health sciences, 030104 developmental biology, Internal medicine, Medicine, Portal hypertension, In patient, business, Oral therapy
Published
2018
Full Text
View/download PDF

19. Acute hemodynamic response to beta-blockers: factors influencing its outcome

Author

A. Estebanez, Alexander Cuadrado, Susana Llerena, Emilio Fábrega, José Ignacio Fortea, Javier Crespo, P. Ruiz, Angela Puente, Fernando Casafont, JoséA. Cabezas, M.T. Arias-Loste, and Silvia Alvarez

Subjects
medicine.medical_specialty, Hepatology, Haemodynamic response, business.industry, Internal medicine, medicine, Cardiology, Beta (finance), business, Outcome (game theory), Surgery
Published
2017
Full Text
View/download PDF

21. P0158 : Influence of sustained viral response in the regression of fibrosis and portal hypertension in cirrhotic HCV genotype 1 patients treated with triple therapy

Author

M.T. Arias Loste, A. Estebanez, José Ignacio Fortea, Javier Crespo, Emilio Fábrega, Alexander Cuadrado, Fernando Casafont, Angela Puente, and Joaquín Cabezas

Subjects
medicine.medical_specialty, Hepatology, Hcv genotype 1, business.industry, Fibrosis, Internal medicine, medicine, Sustained viral response, Portal hypertension, business, medicine.disease, Gastroenterology
Published
2015
Full Text
View/download PDF

22. P0089 : Plasma betatrophin levels in patients with liver cirrhosis

Author

Javier Crespo, Mayte García-Unzueta, M.T. Arias, Angela Puente, Joaquín Cabezas, Susana Llerena, Cristina Alonso, José A. Amado, Paula Iruzubieta, Alexander Cuadrado, and Emilio Fábrega

Subjects
medicine.medical_specialty, Cirrhosis, Hepatology, business.industry, Betatrophin, Internal medicine, medicine, In patient, medicine.disease, business, Gastroenterology
Published
2015
Full Text
View/download PDF

24. 942 LONG-TERM SURVIVAL AFTER VARICEAL BLEEDING: INFLUENCE OF EARLY EVENTS AND EVENTUAL RETURN TO THE COMPENSATED STAGE OF CIRRHOSIS

Author

Carlos Ferre Aracil, Virginia Hernández-Gea, C. Villanueva, Maria A. Poca, J. Llaó, Isabel Graupera, Mar Concepción, Carlos Guarner, Angela Puente, Alan Colomo, and Josep Miñana

Subjects
Variceal bleeding, medicine.medical_specialty, Cirrhosis, Hepatology, business.industry, Long term survival, medicine, Stage (cooking), business, medicine.disease, Surgery
Published
2011
Full Text
View/download PDF

25. O17 IMPACT OF ANTICOAGULANT THERAPY ON UPPER GASTROINTESTINAL BLEEDING (UGI) IN PATIENTS WITH LIVER CIRRHOSIS. RESULTS FROM A RETROSPECTIVE MULTICENTRIC CASE–CONTROL STUDY

Author

J. Martínez Gonzalez, Virginia Hernández-Gea, Angela Puente, Salvador Augustin, Jaime Bosch, A. Albillos, Marina Berenguer, Federica Cerini, Carmen Vinaixa, C. Villanueva, R. Bañares, J.C. Garcia-Pagan, Elba Llop, and Meritxell Casas

Subjects
medicine.medical_specialty, Cirrhosis, Hepatology, business.industry, Case-control study, medicine.disease, Gastroenterology, Internal medicine, Ascites, medicine, Portal hypertension, Upper gastrointestinal bleeding, medicine.symptom, business, Complication, Hepatic encephalopathy, Carvedilol, medicine.drug
Abstract

Background and Aims: Portal hypertension leads to most complication of cirrhosis. Most complications are ameliorated by beta-blockers. Acute hemodynamic response is a recent modality of determining HVPG response. Aims: We aimed to assess the acute effect of Carvedilol on HVPG and its impact on outcome in cirrhotics over a 6-month period. Methods: Patients requiring beta-blocker therapy were subjected to HVPG measurement. After HVPG they were given Tab. Carvedilol 25mg and repeat HVPG performed after one hour. Acute responders (defined as a HVPG 10%. There were no baseline differences between two groups. On follow-up, complications like ascites and hepatic encephalopathy were significantly less common in acute responder group (p 0.05). Repeat HVPG after a median period of 6 months performed in 41 of 49 patients in the acute responder group. Out of 41 patients 35 (85%) patients were still responders (long term responders) and 6 (15%) patient were non long term responders. Conclusions: Determination of acute response to carvedilol is a convenient and rapid way to identify responders. It is an excellent prognostic marker as acute responders develop less complications.

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results